In addition, mice injected with BON-1 cells and treated with octreotide, a SSA, or bevacizumab, a Vascular Endothelial Growth Factor (VEGF) inhibitor, developed fewer liver metastases and manifestations of CS, including valvular heart disease, compared to untreated control [55]. The gene discussed is VEGFA; the disease is heart valve disorder.